Last edition
News about
Gilead and Lakefront Complete Acquisition of Ouro Medicines
Gilead Sciences and Lakefront have completed the acquisition of Ouro Medicines, expanding their inflammation and autoimmune disease pipeline. The companies will jointly advance gamgertamig, a potential first-in-class and best-in-class T-cell engager therapy designed to address unmet needs in autoimmune disorders.
Agilent Technologies has received FDA approval to expand the use of its PD-L1 IHC 22C3 pharmDx test on the Dako Omnis platform, broadening access to PD-L1 testing for four additional tumour types and supporting streamlined pathology laboratory operations.
Omnix Medical has initiated patient dosing in its Phase 2 clinical trial of OMN6, a novel antimicrobial peptide designed to treat severe multidrug-resistant Acinetobacter baumannii infections, a critical global health threat with limited treatment options.
Sygnature Discovery Partners with DaltonTx to Advance AI-Driven Drug Discovery
Sygnature Discovery has partnered with DaltonTx to enhance Artificial Intelligence (AI)-enabled drug discovery capabilities, accelerating medicinal chemistry decision-making while maintaining robust data security standards to support faster and more efficient therapeutic research and development.
Alembic Pharma Receives USFDA Approval for Haloperidol Tablets
Alembic Pharmaceuticals has received final US FDA approval for Haloperidol Tablets USP in multiple strengths. The medication is indicated for the management of psychotic disorders and the treatment of tics and vocal utterances associated with Tourette’s Disorder in both children and adults, expanding Alembic’s US CNS product portfolio.
Glenmark Launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials
Glenmark Pharmaceuticals Inc., USA has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), a bioequivalent and therapeutically equivalent generic version of Vimpat Injection.
Johnson & Johnson's Nipocalimab Shows Sustained Disease Reduction in Lupus Phase 2 Study
The monoclonal antibody met its primary endpoint in the JASMINE trial and demonstrated continued improvements in disease activity through 52 weeks in adults with moderate-to-severe systemic lupus erythematosus.
Telangana DCA Busts Illegal Sale of Codeine and Tramadol-Based Drugs in Medchal-Malkajgiri
The Telangana Drugs Control Administration conducted a raid on a pharmacy in Medchal-Malkajgiri district, seizing codeine-based cough syrups and tramadol-containing capsules being sold in violation of drug regulations.
HBSUK and Hexaware Partner to Digitise Healthcare Workforce Management
HBSUK and Hexaware Technologies launches digital workforce management solution to accelerate clinician onboarding, enhance compliance processes and support healthcare providers in addressing growing workforce and patient care demands.
Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE, First Market Outside the US
UAE becomes first country outside the United States to offer the oral semaglutide treatment for obesity, marking a key step in Novo Nordisk’s global expansion plans.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy